ArticleAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons2026
Impact and outcomes after desensitization therapy in highly sensitized heart transplant candidates.
Article in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The efficacy and posttransplant outcomes of desensitization therapy in highly sensitized heart transplantation (HT) candidates are unknown. In this retrospective cohort study, 57 HT candidates with pre-HT calculated panel reactive antibody (cPRA) level of >50% for anti-human leukocyte antigen antibodies with mean fluorescence intensity >10 000, who were treated with desensitization therapy, were identified. Posttreatment cPRA was determined for all patients, and follow-up data and outcomes were determined from review of the medical record. Bortezomib/plasmapheresis, and rituximab or obinutuzumab with intravenous immunoglobulin led to significant decreases in cPRA calculated for antibodies with mean fluorescence intensity >10 000 and/or C1q-positive antibodies. After desensitization, 40 patients received HT during the follow-up period. Of the transplanted patients, 17 patients experienced elimination or a decrease in donor-specific antibodies that allowed them to receive an HT that would not have been possible prior to desensitization therapy. Transplanted patients had higher rates of antibody-mediated rejection than the general national HT population, but similar 5-year survival and rates of cardiac allograft vasculopathy or graft dysfunction. Safety outcomes, including malignancy and infections, occurred at acceptable rates. Thus, desensitization therapies for highly sensitized HT candidates help to broaden the donor pool and facilitate HT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.